NCT03733223 is a clinical trial of Ateptidase in Ischemic Stroke, sponsored by Zhujiang Hospital.

Who is sponsoring NCT03733223?

NCT03733223 is sponsored by Zhujiang Hospital.

What drugs are being tested in NCT03733223?

Interventions in NCT03733223: Ateptidase.

What condition does NCT03733223 study?

NCT03733223 studies Ischemic Stroke.

Is NCT03733223 still recruiting?

NCT03733223 is currently status unknown. Last updated 17 March 2019.

Last reviewed 2019-03-17 · How we verify

NCT03733223

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relationships Among FVIII, t-PA/PAI-1, and MMP-9 Levels and Intracranial Hemorrhage Complications After Thrombolysis With Alteplase in Patients With Acute Ischemic Stroke: Protocol for a Multicenter Retrospective Study

Status unknown Last updated 17 March 2019

What this trial tests

trial testing Ateptidase in Ischemic Stroke in 350 participants. Status unknown.

Timeline

12 October 2018

Primary endpoint
1 June 2020

1 December 2020

Quick facts

Lead sponsor	Zhujiang Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	350
Start date	12 October 2018
Primary completion	1 June 2020
Estimated completion	1 December 2020
Sites	1 location across China

Drugs / interventions tested

Ateptidase — full drug profile →

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

Zhujiang Hospital

Who can join

Adults 18 to 85, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Intracranial hemorrhage
Time frame: 3 days
The occurrence of intracranial haemorrhage adverse reactions in ischemic stroke patients receiving thrombolytic therapy by alteplase

Sponsor's own description

The primary aim of the study is to investigate the relationships among FVIII, t-PA/PAI-1, MMP-9 levels, and intracranial hemorrhage after thrombolysis with alteplase using a combined analysis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in development of biomarkers for brain damage and ischemia.
Karimova D, Rostami E, Chubarev VN, Tarasov VV, et al · · 2024 · cited 5× · PMID 39001884 · DOI 10.1007/s11033-024-09708-x

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Zhujiang Hospital trials

Trials by the same sponsor.

NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03733223 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
Last refreshed: 17 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03733223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing